Mirum and Incyte gain approval of zilurgisertib for rare bone disorder

Mirum and Incyte gain approval of zilurgisertib for rare bone disorder

FDA approves Mirum/Incyte’s Atebrioz (zilurgisertib) for fibrodysplasia ossificans progressiva, an ultra-rare bone disease. Read more here.